12:00 AM
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

JX-594: Phase IIa started

Jennerex began an open-label, Canadian Phase IIa trial to evaluate intratumoral and IV JX-594 in about 20 patients with colorectal cancer metastases in the liver who are undergoing liver resection.

Transgene has exclusive rights from Jennerex to develop...

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >